|
| 34328221 | Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations. | J Clin Pharmacol | 2022 |
| 36611850 | Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin. | Cells | 2022 |
| 35191192 | Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors. | Clin Transl Sci | 2022 |
| 35014203 | A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development. | Clin Transl Sci | 2022 |
| 35143713 | Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports. | CPT Pharmacometrics Syst Pharmacol | 2022 |
| 34524700 | Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. | J Clin Pharmacol | 2022 |
| 33035445 | Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. | Annu Rev Pharmacol Toxicol | 2021 |
| 33892143 | Towards population-specific pharmacogenomics in the era of next-generation sequencing. | Drug Discov Today | 2021 |
| 34404115 | Perspective on model-informed drug development. | CPT Pharmacometrics Syst Pharmacol | 2021 |
| 34284600 | Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research. | Pharmacogenomics | 2021 |
| 33449439 | Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. | CPT Pharmacometrics Syst Pharmacol | 2021 |
| 32329770 | Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. | JAMA Netw Open | 2020 |
| 33025766 | A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches. | Clin Pharmacol Drug Dev | 2020 |
| 33235392 | FDALabel for drug repurposing studies and beyond. | Nat Biotechnol | 2020 |
| 32765265 | Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy. | Front Pharmacol | 2020 |
| 32335903 | Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities. | Br J Pharmacol | 2020 |
| 32335844 | A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus. | J Pharmacokinet Pharmacodyn | 2020 |
| 30716169 | Is Bioequivalence Established Based on the Reference-Scaled Average Bioequivalence Approach Relevant to Chronic Administration of Phenytoin? Perspectives Based on Population Pharmacokinetic Modeling and Simulations. | J Clin Pharmacol | 2019 |
| 31087554 | Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study. | J Clin Pharmacol | 2019 |
| 31087553 | Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products. | J Clin Pharmacol | 2019 |
| 31087551 | An Integrated Bioinformatics and Quantitative Modeling Approach to Investigate Potential Claims of Oral Generic Drug Product Bioinequivalence: Introduction. | J Clin Pharmacol | 2019 |
| 28858397 | Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials. | J Clin Pharmacol | 2018 |
| 29935299 | Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products. | J Pharm Sci | 2018 |
| 30255663 | Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities. | CPT Pharmacometrics Syst Pharmacol | 2018 |
| 30043511 | A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. | CPT Pharmacometrics Syst Pharmacol | 2018 |
| 30260082 | Establishing a Multidisciplinary Framework to Study Drug-Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate. | CPT Pharmacometrics Syst Pharmacol | 2018 |
| 30377889 | A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans. | J Pharmacokinet Pharmacodyn | 2018 |
| 29485684 | Regulatory Perspectives in Pharmacometric Models of Osteoporosis. | J Clin Pharmacol | 2018 |
| 29052220 | Efficacy From Strange Sources. | Clin Pharmacol Ther | 2018 |
| 29197167 | To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs. | Clin Pharmacol Drug Dev | 2018 |
| 27557470 | Identifying clinically relevant sources of variability: The clopidogrel challenge. | Clin Pharmacol Ther | 2017 |
| 28162967 | Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine. | J Chromatogr B Analyt Technol Biomed Life Sci | 2017 |
| 28182269 | Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. | Clin Pharmacol Ther | 2017 |
| 28466392 | Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now. | Pharm Res | 2017 |
| 28585859 | Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. | J Cardiovasc Pharmacol Ther | 2017 |
| 27040602 | How Informative Are Drug-Drug Interactions of Gene-Drug Interactions? | J Clin Pharmacol | 2016 |
| 26288087 | Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). | J Bone Miner Res | 2016 |
| 26524713 | Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. | Eur J Pharm Sci | 2016 |
| 26470760 | Are We Getting the Best Return on Investment From Clinical Drug-Drug Interaction Studies? | J Clin Pharmacol | 2016 |
| 27647667 | Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network. | CPT Pharmacometrics Syst Pharmacol | 2016 |
| 27197625 | Anticoagulants: What is new and what is the standard? | Clin Pharmacol Ther | 2016 |
| 27287422 | Improving drug safety with a systems pharmacology approach. | Eur J Pharm Sci | 2016 |
| 27251780 | Systems pharmacology to predict drug safety in drug development. | Eur J Pharm Sci | 2016 |
| 25559342 | Clinical pharmacokinetics and pharmacodynamics of clopidogrel. | Clin Pharmacokinet | 2015 |
| 27548289 | Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models. | CPT Pharmacometrics Syst Pharmacol | 2015 |
| 26186657 | Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. | Ther Drug Monit | 2015 |
| 26225258 | Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making. | CPT Pharmacometrics Syst Pharmacol | 2015 |
| 24286486 | Clinical implementation of genetic testing in medicine: a US regulatory science perspective. | Br J Clin Pharmacol | 2014 |
| 25271939 | Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. | CPT Pharmacometrics Syst Pharmacol | 2014 |
| 25141898 | Pharmacogenetic research in partnership with American Indian and Alaska Native communities. | Pharmacogenomics | 2014 |